According to these data, Negri and colleagues evaluated PTEN expression by immunofluorescence both in primary and metastatic sites in CRC patients treated with cetuximab and they found that the loss of PTEN expression in metastatic sites was negatively associated with response (50). This evidence concerns the gene PTEN and colorectal carcinoma.